Loss of Her-2 expression after neo-adjuvant therapy with dual anti-Her-2 agents (Pertuzumab/Herceptin) with chemotherapy in locally advanced Her-2 positive breast cancer.-MedSci.cn

Loss of Her-2 expression after neo-adjuvant therapy with dual anti-Her-2 agents (Pertuzumab/Herceptin) with chemotherapy in locally advanced Her-2 positive breast cancer.

Gupta, NK; Giblin, E; Spivey, T; Govert, K; Leagre, CA; Liebross, RH; Schmidt, K; Heckman, P; Burnett, R; Yadav, R; Tutterrow, R; Beaudrie, N; Durk, J; Tumati, V; Dugan, T; Paul, R; Sando, I; Donnelly, J

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (15):

科室
- - 订阅+
  - 更多科室
工具
服务